NOX1抗体

+ +

•  

   

     Confocal Immunofluorescence analysis of HL60 cells using CD18 mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye.    

  
  

•  

   

     Confocal Immunofluorescence analysis of BCBL-1 cells (left) and L1210 cells (right) using CD18 mouse mAb (red). Blue: DRAQ5 fluorescent DNA dye.    

  
  

The NOX1 antibody is a research tool targeting NADPH oxidase 1 (NOX1), a member of the NOX family of enzymes responsible for reactive oxygen species (ROS) generation. NOX1 is primarily expressed in colon epithelial cells, vascular smooth muscle, and phagocytic cells, where it catalyzes superoxide anion production via electron transport across membranes. Its activity is tightly regulated by binding partners like NOXO1 and NOXA1. Research links NOX1 to cellular processes including proliferation, apoptosis, and signal transduction, with dysregulation implicated in pathologies such as cancer, cardiovascular diseases, and inflammatory bowel disease (e.g., colitis-associated carcinogenesis).

NOX1 antibodies are widely used in Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to study protein expression, localization, and disease mechanisms. Specificity is critical due to structural similarities among NOX isoforms (NOX1-5. DUOX1/2). Many commercial antibodies target unique epitopes in cytoplasmic domains or extracellular loops, though cross-reactivity remains a challenge. Validation often involves knockout cell lines or tissues to confirm signal absence.

Challenges include variable antibody performance across species (human, mouse, rat) and tissue fixation methods. Some clones may recognize precursor forms or degradation products. Researchers prioritize antibodies validated in peer-reviewed studies for specific applications. Recent advances in monoclonal antibody technology have improved NOX1 detection reliability, aiding mechanistic studies of oxidative stress-related diseases and therapeutic target exploration.